Business
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
SOUTH SAN FRANCISCO, Calif., November 26, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented exploratory data at The Menopause Society 2025 Annual Meeting in Orlando, Florida. These findings demonstrate PH80’s potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms (hot flashes) d
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/00ec249c9459b9c2527908d8124ac7a3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H5JwNoZn_mxhW.MKAv9oNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/00ec249c9459b9c2527908d8124ac7a3","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/npoIKae9JuIq6VNK857ylQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/00ec249c9459b9c2527908d8124ac7a3","width":1200,"height":325}},"lazy":false},{"type":"text","content":"Research supports the product candidate’s non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkers","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., November 26, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented exploratory data at The Menopause Society 2025 Annual Meeting in Orlando, Florida. These findings demonstrate PH80’s potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms (hot flashes) due to menopause.","length":533,"tagName":"p"},{"type":"text","content":"The research presented by Vistagen supports PH80’s ability to reduce autonomic nervous system activity after intranasal administration and noted that PH80 was not absorbed into the blood in humans. Nonclinical studies demonstrated that PH80 had no binding activity on steroid hormones or neurotransmitter receptors in vitro and had no effects on reproductive organs in laboratory mice and rats.","length":394,"tagName":"p"},{"type":"text","content":""This research significantly enhances our understanding of PH80’s proposed mechanism of action, demonstrating its rapidly-acting, neurocircuitry-focused effects without entering the bloodstream in human volunteers and without binding to steroid hormone receptors or neurotransmitter receptors associated with abuse. The research also shows PH80’s rapid impact on physiologic biomarkers of autonomi...